A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Trial details
- Registry ID
- NCT06774131
- Drugs studied
- UGN-104
TrialRedline tracks 5 clinical trials sponsored by UroGen Pharma Ltd.: 5 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131 | UGN-104 | Recruiting | 2027-03Estimated |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT05243550 | UGN-102 | Active not recruiting | 2023-04-26Actual |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299 | UGN-103 | Completed | 2025-09-11Actual |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05136898 | UGN-102 | Completed | 2023-02-02Actual |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931 | TURBT, UGN-102 | Terminated | 2023-03-17Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptIn August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | adults with recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptOur NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent LG-IR-NMIBC | Open original sourceRead source excerptIn October 2026, the FDA accepted for review UroGen’s NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027. The NDA is based on clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter trial evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
Names as written in the registry records.
NCT06331299 · UroGen Pharma Ltd.
Before: Active not recruiting. After: Completed.
NCT06331299 · UroGen Pharma Ltd.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Complete response rate (CRR) Description: CRR is defined as the proportion of patients who achieved CR at the 3-month Visit. Time frame: 3 months. After: Measure: Complete Response Rate (CRR) Description: CRR is defined as the proportion of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology. Time frame: 3 months.
NCT06774131 · UroGen Pharma Ltd.
Before: Oct 2026. After: Mar 2027.
NCT06774131 · UroGen Pharma Ltd.
Before: 50 participants (planned). After: 70 participants (planned).
Before: 31 Mar 2026. After: Oct 2026.
NCT06331299 · UroGen Pharma Ltd.
Before: Estimated. After: Actual.
Before: 92 participants (planned). After: 99 participants (actual).
Before: Estimated. After: Actual.
Before: Aug 2025. After: 11 Sep 2025.
Before: Recruiting. After: Active not recruiting.